^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Chronic Myeloid Leukemia
    Drug:Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    07/01/2013
    Excerpt:
    Iclusig is indicated in adult patients with:...chronic-phase, accelerated-phase or blast-phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib, who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate...
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    Iclusig is a kinase inhibitor indicated for the:…Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Ph+ ALL for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated….Iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase CML.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Ponatinib is a treatment option for patients with a T315I mutation and/or CP-CML with resistance or intolerance to at least 2 prior TKIs or for patients with AP-CML or BP-CML for whom no other TKI is indicated.